Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Mus musculus | abhydrolase domain containing 6 | Starlite/ChEMBL | No references |
Mus musculus | diacylglycerol lipase, beta | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Plasmodium falciparum | epoxide hydrolase 2 | abhydrolase domain containing 6 | 336 aa | 295 aa | 19.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | hypothetical protein, conserved | 0.0173 | 0 | 0.5 |
Trypanosoma brucei | lipase domain protein, putative | 0.0173 | 0 | 0.5 |
Trypanosoma brucei | lipase domain protein, putative | 0.0173 | 0 | 0.5 |
Echinococcus granulosus | sn1 specific diacylglycerol lipase beta | 0.0173 | 0 | 0.5 |
Trichomonas vaginalis | lipase containing protein, putative | 0.0173 | 0 | 0.5 |
Trichomonas vaginalis | lipase containing protein, putative | 0.0173 | 0 | 0.5 |
Loa Loa (eye worm) | lipase | 0.0173 | 0 | 0.5 |
Echinococcus multilocularis | sn1 specific diacylglycerol lipase beta | 0.0173 | 0 | 0.5 |
Mycobacterium ulcerans | 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoate hydrolase BphD | 0.0499 | 1 | 0.5 |
Brugia malayi | Lipase family protein | 0.0173 | 0 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0173 | 0 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0173 | 0 | 0.5 |
Onchocerca volvulus | 0.0173 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | 0.001 uM | PubChem BioAssay. Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based dose-response biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of antitarget ABHD6 in vitro, set 2. (Class of assay: confirmatory) | ChEMBL. | No reference |
IC50 (functional) | 0.056 uM | PubChem BioAssay. Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based dose-response biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of DAGLb in vitro. (Class of assay: confirmatory) | ChEMBL. | No reference |
IC50 (functional) | 0.1 uM | PubChem BioAssay. Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): LCMS-based biochemical dose response assay. (Class of assay: confirmatory) | ChEMBL. | No reference |
Inhibition (binding) | = 66 % | Inhibition of FP-rhodamine-labelled recombinant mouse DAGLbeta expressed in HEK293T cells at 100 nM preincubated for 30 mins followed by FP-rhodamine labelling measured after 30 mins by gel-based competitive ABPP assay | ChEMBL. | 24152295 |
Inhibition (binding) | = 89 % | Inhibition of ABHD6 in FP-rhodamine-labelled mouse brain membrane at 10 nM preincubated for 30 mins followed by FP-rhodamine labelling measured after 30 mins by gel-based competitive ABPP assay | ChEMBL. | 24152295 |
Inhibition (binding) | = 100 % | Inhibition of FP-rhodamine-labelled recombinant mouse DAGLbeta expressed in HEK293T cells at 10 uM preincubated for 30 mins followed by FP-rhodamine labelling measured after 30 mins by gel-based competitive ABPP assay | ChEMBL. | 24152295 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.